These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 7173983)
1. Circulating inhibitory factors in Hodgkin's disease: effect on binding of 125I-PHA to lymphocytes. Moghe MV; Advani SH; Gangal SG Indian J Exp Biol; 1982 Jul; 20(7):517-21. PubMed ID: 7173983 [No Abstract] [Full Text] [Related]
2. Effect of circulating soluble inhibitory factors in Hodgkin's disease on the stimulating activity of PHA pulsed lymphocyte lysates. Moghe MV; Advani SH; Gangal SG Indian J Med Res; 1983 Jul; 78 Suppl():88-94. PubMed ID: 6654435 [No Abstract] [Full Text] [Related]
3. Impairment of lymphocyte transformation by plasma from patients with advanced Hodgkin's disease. Sugden PJ; Lilleyman JS Cancer; 1980 Mar; 45(5):899-905. PubMed ID: 7260841 [TBL] [Abstract][Full Text] [Related]
4. Autoradiography of activated lymphocytes in the blood in Hodgkin's disease. Folb PI; Ramot B Isr J Med Sci; 1973 Jul; 9(7):923-5. PubMed ID: 4732929 [No Abstract] [Full Text] [Related]
6. Impaired phytohaemagglutinin-induced cytotoxicity in vitro of lymphocytes from patients with Hodgkin's disease or chronic lymphatic leukaemia. Holm G; Perlmann P; Johansson B Clin Exp Immunol; 1967 May; 2(3):351-60. PubMed ID: 6035198 [TBL] [Abstract][Full Text] [Related]
7. [Delayed reaction of lymphocytes in Hodgkin's disease to phytophaemagglutinin (PHA)]. Havemann K Ger Med Mon; 1969 May; 14(5):243-6. PubMed ID: 5807508 [No Abstract] [Full Text] [Related]
8. [Granulocyte turnover in advanced Hodgkin's disease]. Prazmowska-Owczarek B; Hansz J Z Gesamte Inn Med; 1981 Sep; 36(18):678-80. PubMed ID: 7314751 [TBL] [Abstract][Full Text] [Related]
9. Abnormal circulating cells and splenic involvement in Hodgkin's disease. Halie MR; Hamers J; Van Larebeke N; Van Hove WZ; Nieweg HO Neth J Med; 1976; 19(4-5):209-14. PubMed ID: 980189 [No Abstract] [Full Text] [Related]
10. [Plasma fibronectin in normal subjects and in Hodgkin's disease]. Moraleda JM; Batlle J; Fernanda López M; Consuelo López-Berges M; González M; San Miguel J; López Borrasca A Sangre (Barc); 1987; 32(4):465-9. PubMed ID: 3660185 [No Abstract] [Full Text] [Related]
11. [The blood platelets in Hodgkin's disease]. Barry A; Laroche A; De Lage JM Laval Med; 1966 Sep; 37(7):784-7. PubMed ID: 5954205 [No Abstract] [Full Text] [Related]
12. [Mediastinal Hodgkin's disease and non-Hodgkin lymphoma in childhood]. Kuleva SA Vopr Onkol; 2002; 48(6):735-7. PubMed ID: 12530278 [TBL] [Abstract][Full Text] [Related]
13. Evidence for the involvement of monocyte-derived toxic oxygen metabolites in the lymphocyte dysfunction of Hodgkin's disease. Deshazo RD; Ewel C; Londono S; Metzger Z; Hoffeld JT; Oppenheim JJ Clin Exp Immunol; 1981 Nov; 46(2):313-20. PubMed ID: 7337972 [TBL] [Abstract][Full Text] [Related]
15. Plasma zinc levels in Hodgkin's disease. Evaluation of 37 cases. Gobbi PG; Scarpellini M; Minoia C; Pozzoli L; Perugini S Haematologica; 1978 Apr; 63(2):143-55. PubMed ID: 98399 [No Abstract] [Full Text] [Related]
16. [Disorders of the hematopoietic system in patients with Hodgkin's disease before treatment]. Paluszewska M; Rokicka M; Kuratowska Z Pol Tyg Lek; 1987 Apr; 42(17):497-9. PubMed ID: 3615279 [No Abstract] [Full Text] [Related]
20. [Considerations on the action of phytohemagglutinins, tuberculin antigens and Kveim's antigen on lymphocyte cultures of patients with sarcoidosis and Hodgkin's disease]. Ricci M; Lenzini L; Passaleva A; Ricca M Folia Allergol (Roma); 1966; 13(1):11-4. PubMed ID: 5929596 [No Abstract] [Full Text] [Related] [Next] [New Search]